Other Clinical Trial - Evaluating the Impact of SomaSignal Tests on

Status Recruiting

Clinical Trial Summary

Feasibility Study Informed consent will be obtained using an IRB-approved form. The first 12 consenting patients will be placed in the planned assessment group for feasibility and will not be randomized. These participants will undergo visits and blood draw collection at 3 months. They will be informed of their SomaSignal Test results at baseline and 3 months. Recommendations for any medical management changes will be made based on an understanding of those results. Randomized Study The succeeding 200 participants will be randomized using permuted mixed block randomization, in a 2:1 ratio, i.e., 2 participants to Group 1 (informed of their test results) and 1 participant to Group 2 (uninformed of their test results). At enrollment, and for 6 months thereafter, clinical information will be obtained from each participant's medical records, and/or directly from the participant during procedures, treatments, study-specific visits, and/or follow-up visits. Data collected for the study will have data linkage at SomaLogic, Inc., where data analysis will be done. At baseline and 6-months (+30 days) post-enrollment, patients will undergo a patient visit and blood collection. Blood will be collected as a stand-alone sample collection, or when other ordered lab work is done, or from access lines inserted during a usual or specialized care. Samples will be sent to the Intermountain Central laboratory for clinical testing. A sample will also be processed and shipped to SomaLogic, Inc. for analysis at baseline and 6 months. For the informed arm, the SomaSignal Test reports will be provided at the time they are available (2 to 4 weeks after the blood draw). Any recommended changes in medical management will be recorded in the case report forms and will be verified by the Principal Investigator. For the uninformed arm, the SomaSignal Test results will not be provided to the study team until after the 6-month post-test visit. Adjustments, if any, would be made to the participant's management at that time.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04836117
Study type	Interventional
Source	Intermountain Health Care, Inc.
Contact	Darija Rujaic Ward
Phone	8015074701
Email	Darija.RujaicWard@imail.org
Status	Recruiting
Phase	N/A
Start date	August 12, 2021
Completion date	August 12, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05009251` - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake	N/A
Recruiting	`NCT04356924` - Psychological Treatment to Support the Consequences of Cognitive Impairment	N/A
Completed	`NCT05509049` - Precision Nudging Drives Wellness Visit Attendance at Scale	N/A
Completed	`NCT03904992` - Intervention With a Progressive Web App for the Promotion of Healthy Habits in Preschoolers	N/A
Completed	`NCT05509270` - Efficacy of Communication Modalities for Promoting Flu Shots	N/A
Completed	`NCT03167372` - Pilot Comparison of N-of-1 Trials of Light Therapy	N/A
Completed	`NCT03081520` - Affective Responses Following Aerobic Exercise With Different Intensities	N/A
Completed	`NCT05012163` - Lottery Incentive Nudges to Increase Influenza Vaccinations	N/A
Completed	`NCT03982095` - Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
Completed	`NCT02777086` - Sustainable HIV Risk Reduction Strategies for Probationers	N/A
Completed	`NCT02996864` - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II	N/A
Not yet recruiting	`NCT06071130` - Emotion, Aging, and Decision Making	N/A
Active, not recruiting	`NCT04152824` - Readiness Supportive Leadership Training	N/A
Recruiting	`NCT05541653` - The IGNITE Study on Concentrated Investment in Black Neighborhoods	N/A
Completed	`NCT03875768` - Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure	N/A
Completed	`NCT04089020` - Walking to School Supports	N/A
Completed	`NCT03646903` - Reducing Help-Seeking Stigma in Young Adults at Elevated Suicide Risk	N/A
Completed	`NCT03548077` - POWERPLAY: Promoting Men's Health at Work	N/A
Recruiting	`NCT05249465` - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention	N/A
Completed	`NCT04323137` - Encouraging Flu Vaccination Among High-Risk Patients Identified by ML	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study — SomaSignal

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms